- cafead   Jun 20, 2022 at 10:42: AM
via The U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee (PDAC) voted against Acadia Pharmaceutical’s supplemental New Drug Application (sDNA) of Nuplazid (pimavanserin) tablets for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis by a vote of 9-3.
article source
article source